Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

ng of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 26 proprietary products in the U.S. and approximately 1,025 products globally outside of the U.S. For more information, visit http://www.barrlabs.com.

Forward-Looking Statements

Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmace
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 HIGHLIGHTS:Q2 2015 Results (all ... , Reported sales were $697 million compared to $701 ... organically by 8%, and changes in foreign currency exchange ... by 1%. , By business unit, organic sales ... 11% in SAFC Commercial. , Reported diluted EPS ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
(Date:7/29/2015)... , July 30, 2015 According to ... - Growth, Trends & Forecasts (2015-2020), , published by Mordor ... 30.25 billion by the end of 2020, with ... for more than 40% of the global market size. The ... a CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)... MONTREAL , July 29, 2015 /PRNewswire/ - BioAmber Inc. ... Laurin , the Company,s Chief Financial Officer has resigned.  ... former Chief Financial Officer who retired in December 2014, ... search for a permanent successor.     Andy ... Mr. Laurin and ensure a smooth transition.  Andy was ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... PHILADELPHIA, May 28 Premier Research Group plc ... of Anthony Faragasso, MD as Executive Director and ... position, Dr. Faragasso will lead,the global Medical Management ... and safety services, Dr. Faragasso brings to ...
... ... Manufacturing Experience -, SAN DIEGO, May 28 ... Gordon H.,Busenbark to the company,s board of directors. Mr. Busenbark ... privately,held development-stage specialty pharmaceuticals company focused on,diseases of the central ...
... launch of a new collaborative website initially focusing on ... WikiProfessional technology underlying the site has been developed based ... open access journal Genome Biology, WikiProteins provides a method ... The article is written by Barend Mons of the ...
Cached Biology Technology:Premier Research Names Anthony Faragasso, MD as Executive Director and Global Head of Medical Management and Safety 2Nventa Appoints Gordon H. Busenbark to Board of Directors 2Large-scale community protein annotation -- WikiProteins 2
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting ... the addition of two new team members. ... David Raviv will act as head of strategic ... to providing the most secure solutions for the enterprise market. ... 7 Technologies, a provider of security and management products, which ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... North Carolina State University researcher has shown that water-gel-based ... solar cells to produce electricity. The findings prove the ... nature. They also have the potential to be less ... silicon-based solar cells. The bendable devices are composed ...
... , This release is available in Spanish ... a popular native Hawaiian fruit, has been released by U.S. ... cooperators. ,Ōhelo ( Vaccinium reticulatum Smith ) is ... found at high elevations on the islands of Maui and ...
... an effective vaccine for malaria is a step closer following ... to infect human cells. The discovery, by researchers at The ... new vaccine target through which infection with the deadly disease ... people contract malaria, and more than one million, mostly children, ...
Cached Biology News:Mimicking nature, water-based 'artificial leaf' produces electricity 2Scientists release first cultivated ohelo berry for Hawaii 2Malaria's newest pathway into human cells identified 2
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
Intestinal Epithelium Differentiation Environment...
Hepatocyte Differentiation Environment...
Biology Products: